ARS Pharmaceuticals, Inc. SPRY Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s net change in cash?
- ARS Pharmaceuticals, Inc. (SPRY) reported net change in cash of -$17M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
- ARS Pharmaceuticals, Inc.'s net change in cash decreased by 55.2% year-over-year, from -$10.95M to -$17M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s net change in cash?
- Over 2 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s net change in cash has grown at a -48.3% compound annual growth rate (CAGR), from $35.54M to -$9.5M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.